{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:24:23Z","timestamp":1790310263139,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of the resistance is the major problem in cancer therapy. Docetaxel is a taxol alkaloid that is frequently used in metastatic breast cancer. However, resistance often limits the usefulness of this drug in many breast cancer patients. Manipulation of resistant cells to re-sensitize to the therapeutic effect of docetaxel is current strategy to overcome this problem. Here, we have introduced \u2018Iturin A\u2019 as a potent chemosensitizer in docetaxel resistant breast cancer cells. Combination of Iturin A and docetaxel treatment significantly hampered the proliferation of docetaxel resistant MDA-MB-231 and MDA-MB-468 breast cancer cells. Cell cycle analysis also showed massive amount of apoptotic population (Sub G0\/G1) in combination therapy. A number of apoptotic and anti-apoptotic proteins were significantly altered in dual drug treated groups. Caspase 3 dependent cell death was observed in dual treatment. Molecular mechanism study showed that over-expression of Akt and its downstream signaling pathway was associated with docetaxel resistance. Iturin A significantly reduced Akt signaling pathway in resistant cells. This mechanistic action might be the reason behind the chemo-sensitization effect of Iturin A in docetaxel resistant breast cancer cells. In conclusion, Iturin A resensitized the resistant breast cancer cells to docetaxel therapy by inhibiting Akt activity.<\/jats:p>","DOI":"10.1038\/s41598-017-17652-z","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T12:36:35Z","timestamp":1512477395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by \u2018Iturin A\u2019 a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium"],"prefix":"10.1038","volume":"7","author":[{"given":"Goutam","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkrishna","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahitosh","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"17652_CR1","doi-asserted-by":"publisher","unstructured":"Zhang, X. H. et al. MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3 beta\/beta-Catenin Signaling Pathway. PLoS One \n                           11, https:\/\/doi.org\/10.1371\/journal.pone.0153194 (2016).","DOI":"10.1371\/journal.pone.0153194"},{"key":"17652_CR2","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1158\/0008-5472.CAN-09-1224","volume":"69","author":"S De","year":"2009","unstructured":"De, S., Cipriano, R., Jackson, M. W. & Stark, G. R. Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells. Cancer Res \n                           69, 8035\u20138042, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1224 (2009).","journal-title":"Cancer Res"},{"key":"17652_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2741\/1592","volume":"10","author":"D Kim","year":"2005","unstructured":"Kim, D. et al. Akt\/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci \n                           10, 975\u2013987, https:\/\/doi.org\/10.2741\/1592 (2005).","journal-title":"Front Biosci"},{"key":"17652_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/onc.2009.300","volume":"29","author":"MR Abedini","year":"2010","unstructured":"Abedini, M. R., Muller, E. J., Bergeron, R., Gray, D. A. & Tsang, B. K. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene \n                           29, 11\u201325, https:\/\/doi.org\/10.1038\/onc.2009.300 (2010).","journal-title":"Oncogene"},{"key":"17652_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature \n                           428, 332\u2013337, https:\/\/doi.org\/10.1038\/nature02369 (2004).","journal-title":"Nature"},{"key":"17652_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2016.02.048","volume":"375","author":"R Bharti","year":"2016","unstructured":"Bharti, R., Dey, G. & Mandal, M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Letters \n                           375, 51\u201361, https:\/\/doi.org\/10.1016\/j.canlet.2016.02.048 (2016).","journal-title":"Cancer Letters"},{"key":"17652_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.leukres.2008.06.010","volume":"33","author":"MG Garcia","year":"2009","unstructured":"Garcia, M. G., Alaniz, L. D., Russo, R. I. C., Alvarez, E. & Hajos, S. E. PI3K\/Akt inhibition modulates multidrug resistance and activates NF-kappa B in murine lymphoma cell lines. Leukemia Res \n                           33, 288\u2013296, https:\/\/doi.org\/10.1016\/j.leukres.2008.06.010 (2009).","journal-title":"Leukemia Res"},{"key":"17652_CR8","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1038\/cddiscovery.2015.61","volume":"1","author":"BS Vinod","year":"2015","unstructured":"Vinod, B. S. et al. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Cell Death Discov \n                           1, 15061, https:\/\/doi.org\/10.1038\/cddiscovery.2015.61 (2015).","journal-title":"Cell Death Discov"},{"key":"17652_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cllc.2012.12.001","volume":"14","author":"SM Gadgeel","year":"2013","unstructured":"Gadgeel, S. M. & Wozniak, A. Preclinical Rationale for PI3K\/Akt\/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer. Clin Lung Cancer \n                           14, 322\u2013332, https:\/\/doi.org\/10.1016\/j.cllc.2012.12.001 (2013).","journal-title":"Clin Lung Cancer"},{"key":"17652_CR10","doi-asserted-by":"publisher","unstructured":"Fujiwara, M. et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Canc Res \n                           27, https:\/\/doi.org\/10.1186\/1756-9966-27-76 (2008).","DOI":"10.1186\/1756-9966-27-76"},{"key":"17652_CR11","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1021\/acs.molpharmaceut.5b00692","volume":"12","author":"S Rajput","year":"2015","unstructured":"Rajput, S. et al. Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Mol Pharm \n                           12, 4214\u20134225, https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00692 (2015).","journal-title":"Mol Pharm"},{"key":"17652_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drudis.2014.09.006","volume":"20","author":"G Dey","year":"2015","unstructured":"Dey, G., Bharti, R., Sen, R. & Mandal, M. Microbial amphiphiles: A class of promising new-generation anticancer agents. Drug Discovery Today \n                           20, 136\u2013146, https:\/\/doi.org\/10.1016\/j.drudis.2014.09.006 (2015).","journal-title":"Drug Discovery Today"},{"key":"17652_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.biotechadv.2013.01.004","volume":"31","author":"SM Mandal","year":"2013","unstructured":"Mandal, S. M., Barbosa, A. E. A. D. & Franco, O. L. Lipopeptides in microbial infection control: Scope and reality for industry. Biotechnol Adv \n                           31, 338\u2013345, https:\/\/doi.org\/10.1016\/j.biotechadv.2013.01.004 (2013).","journal-title":"Biotechnol Adv"},{"key":"17652_CR14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1128\/AAC.05580-11","volume":"56","author":"CD Qian","year":"2012","unstructured":"Qian, C. D. et al. Battacin (Octapeptin B5), a New Cyclic Lipopeptide Antibiotic from Paenibacillus tianmuensis Active against Multidrug-Resistant Gram-Negative Bacteria. Antimicrob Agents Ch \n                           56, 1458\u20131465, https:\/\/doi.org\/10.1128\/Aac.05580-11 (2012).","journal-title":"Antimicrob Agents Ch"},{"key":"17652_CR15","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1039\/C5OB00780A","volume":"13","author":"SA Cochrane","year":"2015","unstructured":"Cochrane, S. A., Lohans, C. T., van Belkum, M. J., Bels, M. A. & Vederas, J. C. Studies on tridecaptin B-1, a lipopeptide with activity against multidrug resistant Gram-negative bacteria. Org Biomol Chem \n                           13, 6073\u20136081, https:\/\/doi.org\/10.1039\/c5ob00780a (2015).","journal-title":"Org Biomol Chem"},{"key":"17652_CR16","doi-asserted-by":"publisher","first-page":"71612","DOI":"10.1039\/C6RA13476A","volume":"6","author":"G Dey","year":"2016","unstructured":"Dey, G. et al. Pre-clinical risk assessment and therapeutic potential of antitumor lipopeptide \u2018Iturin A\u2019 in an in vivo and in vitro model. Rsc Adv \n                           6, 71612\u201371623, https:\/\/doi.org\/10.1039\/c6ra13476a (2016).","journal-title":"Rsc Adv"},{"key":"17652_CR17","doi-asserted-by":"publisher","unstructured":"Dey, G. et al. Marine lipopeptide Iturin A inhibits Akt mediated GSK3 beta and FoxO3a signaling and triggers apoptosis in breast cancer. Sci Rep-Uk \n                           5, https:\/\/doi.org\/10.1038\/Srep10316 (2015).","DOI":"10.1038\/Srep10316"},{"key":"17652_CR18","doi-asserted-by":"publisher","unstructured":"Dobbelstein, M. & Moll, U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13, 179\u2013196, https:\/\/doi.org\/10.1038\/nrd4201 (2014).","DOI":"10.1038\/nrd4201"},{"key":"17652_CR19","doi-asserted-by":"crossref","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu Rev Med \n                           53, 615\u2013627, https:\/\/doi.org\/10.1146\/annurev.med.53.082901.103929 53\/1\/615 [pii] (2002).","DOI":"10.1146\/annurev.med.53.082901.103929"},{"key":"17652_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm1008-1128","volume":"14","author":"K Honma","year":"2008","unstructured":"Honma, K. et al. RPN2 gene confers docetaxel resistance in breast cancer (vol 14, pg 939, 2008). Nature Medicine \n                           14, 1128\u20131128, https:\/\/doi.org\/10.1038\/Nm1008-1128 (2008).","journal-title":"Nature Medicine"},{"key":"17652_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2165\/00003495-200059030-00015","volume":"59","author":"DP Figgitt","year":"2000","unstructured":"Figgitt, D. P. & Wiseman, L. R. Docetaxel - An update of its use in advanced breast cancer. Drugs \n                           59, 621\u2013651, https:\/\/doi.org\/10.2165\/00003495-200059030-00015 (2000).","journal-title":"Drugs"},{"key":"17652_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygeno.2012.11.009","volume":"101","author":"S AbuHammad","year":"2013","unstructured":"AbuHammad, S. & Zihlif, M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics \n                           101, 213\u2013220, https:\/\/doi.org\/10.1016\/j.ygeno.2012.11.009 (2013).","journal-title":"Genomics"},{"key":"17652_CR23","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/bjc.2017.78","volume":"116","author":"K Mittal","year":"2017","unstructured":"Mittal, K. et al. Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer. British journal of cancer \n                           116, 1186\u20131194, https:\/\/doi.org\/10.1038\/bjc.2017.78 (2017).","journal-title":"British journal of cancer"},{"key":"17652_CR24","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1007\/s11095-007-9369-2","volume":"24","author":"VY Chen","year":"2007","unstructured":"Chen, V. Y., Posada, M. M., Zhao, L. & Rosania, G. R. Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance. Pharmaceutical research \n                           24, 2156\u20132167, https:\/\/doi.org\/10.1007\/s11095-007-9369-2 (2007).","journal-title":"Pharmaceutical research"},{"key":"17652_CR25","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1091\/mbc.E02-11-0704","volume":"14","author":"A Rajagopal","year":"2003","unstructured":"Rajagopal, A. & Simon, S. M. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell \n                           14, 3389\u20133399, https:\/\/doi.org\/10.1091\/mbc.E02-11-0704 (2003).","journal-title":"Mol Biol Cell"},{"key":"17652_CR26","doi-asserted-by":"publisher","unstructured":"Li, H. F., Kim, J. S. & Waldman, T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4, https:\/\/doi.org\/10.1186\/1748-717x-4-43 (2009).","DOI":"10.1186\/1748-717x-4-43"},{"key":"17652_CR27","first-page":"3585","volume":"36","author":"H Luo","year":"2016","unstructured":"Luo, H. et al. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Anticancer Research \n                           36, 3585\u20133589 (2016).","journal-title":"Anticancer Research"},{"key":"17652_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/cdd.2012.93","volume":"20","author":"SH Lee","year":"2013","unstructured":"Lee, S. H., Meng, X. W., Flatten, K. S., Loegering, D. A. & Kaufmann, S. H. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ \n                           20, 64\u201376, https:\/\/doi.org\/10.1038\/cdd.2012.93 (2013).","journal-title":"Cell Death Differ"},{"key":"17652_CR29","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NAP Franken","year":"2006","unstructured":"Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat Protoc \n                           1, 2315\u20132319, https:\/\/doi.org\/10.1038\/nprot.2006.339 (2006).","journal-title":"Nat Protoc"},{"key":"17652_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nm0302-216","volume":"8","author":"W Roth","year":"2002","unstructured":"Roth, W. & Reed, J. C. Apoptosis and cancer: When BAX is TRAILing away. Nature Medicine \n                           8, 216\u2013218, https:\/\/doi.org\/10.1038\/Nm0302-216 (2002).","journal-title":"Nature Medicine"},{"key":"17652_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/cdd.2013.139","volume":"21","author":"D Westphal","year":"2014","unstructured":"Westphal, D., Kluck, R. M. & Dewson, G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ \n                           21, 196\u2013205, https:\/\/doi.org\/10.1038\/cdd.2013.139 (2014).","journal-title":"Cell Death Differ"},{"key":"17652_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nm.2385","volume":"17","author":"Q Huang","year":"2011","unstructured":"Huang, Q. et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine \n                           17, 860\u2013U231, https:\/\/doi.org\/10.1038\/nm.2385 (2011).","journal-title":"Nature Medicine"},{"key":"17652_CR33","doi-asserted-by":"publisher","unstructured":"Kim, S. H., Juhnn, Y. S. & Song, Y. S. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci \n                           1095, 82\u201389, https:\/\/doi.org\/10.1196\/annals.1397.012 (2007).","DOI":"10.1196\/annals.1397.012"},{"key":"17652_CR34","doi-asserted-by":"publisher","unstructured":"Singel, S. M. et al. KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer. Neoplasia \n                           16, https:\/\/doi.org\/10.1016\/j.neo.2014.03.008 (2014).","DOI":"10.1016\/j.neo.2014.03.008"},{"key":"17652_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0929-6646(09)60051-6","volume":"108","author":"WC Huang","year":"2009","unstructured":"Huang, W. C. & Hung, M. C. Induction of Akt Activity by Chemotherapy Confers Acquired Resistance. Journal of the Formosan Medical Association \n                           108, 180\u2013194 (2009).","journal-title":"Journal of the Formosan Medical Association"},{"key":"17652_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/mmr_00000145","volume":"2","author":"F You","year":"2009","unstructured":"You, F., Aoki, K., Ito, Y. & Nakashima, S. AKT plays a pivotal role in the acquisition of resistance to 5-fluorouracil in human squamous carcinoma cells. Mol Med Rep \n                           2, 609\u2013613, https:\/\/doi.org\/10.3892\/mmr_00000145 (2009).","journal-title":"Mol Med Rep"},{"key":"17652_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3109\/10428194.2010.551793","volume":"52","author":"SA Maxwell","year":"2011","unstructured":"Maxwell, S. A., Cherry, E. M. & Bayless, K. J. Akt, 14-3-3zeta, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma \n                           52, 849\u2013864, https:\/\/doi.org\/10.3109\/10428194.2010.551793 (2011).","journal-title":"Leuk Lymphoma"},{"key":"17652_CR38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jcb.25091","volume":"116","author":"Z Liu","year":"2015","unstructured":"Liu, Z., Zhu, G. J., Getzenberg, R. H. & Veltri, R. W. The Upregulation of PI3K\/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. Journal of Cellular Biochemistry \n                           116, 1341\u20131349, https:\/\/doi.org\/10.1002\/jcb.25091 (2015).","journal-title":"Journal of Cellular Biochemistry"},{"key":"17652_CR39","doi-asserted-by":"publisher","first-page":"e54193","DOI":"10.1371\/journal.pone.0054193","volume":"8","author":"MP Barr","year":"2013","unstructured":"Barr, M. P. et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One \n                           8, e54193, https:\/\/doi.org\/10.1371\/journal.pone.0054193 (2013).","journal-title":"PLoS One"},{"key":"17652_CR40","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1038\/onc.2015.466","volume":"35","author":"R Bharti","year":"2016","unstructured":"Bharti, R. et al. Diacerein-mediated inhibition of IL-6\/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene \n                           35, 3965\u20133975, https:\/\/doi.org\/10.1038\/onc.2015.466 (2016).","journal-title":"Oncogene"},{"key":"17652_CR41","doi-asserted-by":"publisher","unstructured":"Bharti, R. et al. Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer Lett \n                           388, 292\u2013302, https:\/\/doi.org\/10.1016\/j.canlet.2016.12.021 (2016).","DOI":"10.1016\/j.canlet.2016.12.021"},{"key":"17652_CR42","doi-asserted-by":"publisher","unstructured":"Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1, 1458\u20131461, https:\/\/doi.org\/10.1038\/nprot.2006.238 (2006).","DOI":"10.1038\/nprot.2006.238"},{"key":"17652_CR43","doi-asserted-by":"publisher","unstructured":"Das, S. et al. Antineoplastic and Apoptotic Potential of Traditional Medicines Thymoquinone and Diosgenin in Squamous Cell Carcinoma. PLoS ONE \n                           7, https:\/\/doi.org\/10.1371\/journal.pone.0046641 (2012).","DOI":"10.1371\/journal.pone.0046641"},{"key":"17652_CR44","doi-asserted-by":"publisher","first-page":"9829","DOI":"10.1007\/s13277-015-3758-7","volume":"36","author":"KK Dey","year":"2015","unstructured":"Dey, K. K. et al. Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach. Tumor Biology \n                           36, 9829\u20139837, https:\/\/doi.org\/10.1007\/s13277-015-3758-7 (2015).","journal-title":"Tumor Biology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17652-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T15:53:15Z","timestamp":1671810795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17652-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17652"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17652-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]},"assertion":[{"value":"3 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17324"}}